July 24, 2023 07:21 AM EDTUpdated 09:18 AM
R&D

Ko­di­ak ends at­tempt at an Eylea ri­val as its bi­o­log­ic fails two of three PhI­II tri­als

Kyle LaHucik

Senior Reporter

Ko­di­ak Sci­ences’ at­tempt at mak­ing an Eylea ri­val for pa­tients with var­i­ous eye con­di­tions has come to an end.

The Cal­i­for­nia biotech is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times